Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS

J Card Fail. 2016 Oct;22(10):815-22. doi: 10.1016/j.cardfail.2015.12.017. Epub 2015 Dec 22.

Abstract

Background: The length of hospital stay (LOS) is important in patients admitted for acute heart failure (AHF) because it prolongs an unpleasant experience for the patients and adds substantially to health care costs.

Methods and results: We examined the association between LOS and baseline characteristics, 10-day post-discharge HF readmission, and 90-day post-discharge mortality in 1347 patients with AHF enrolled in the VERITAS program. Longer LOS was associated with greater HF severity and disease burden at baseline; however, most of the variability of LOS could not be explained by these factors. LOS was associated with a higher HF risk of both HF readmission (odds ratio for 1-day increase: 1.08; 95% confidence interval [CI] 1.01-1.16; P = .019) and 90-day mortality (hazard ratio for 1-day increase: 1.05; 95% CI 1.02-1.07; P < .001), although these associations are partially explained by concurrent end-organ damage and worsening heart failure during the first days of admission.

Conclusions: In patients who have been admitted for AHF, longer length of hospital stay is associated with a higher rate of short-term mortality.

Clinical trial registration: VERITAS-1 and -2: Clinicaltrials.gov identifiers NCT00525707 and NCT00524433.

Keywords: Heart failure; length of stay; prognosis.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Aged
  • Analysis of Variance
  • Double-Blind Method
  • Female
  • Heart Failure / diagnostic imaging
  • Heart Failure / drug therapy*
  • Heart Failure / mortality*
  • Hospital Mortality*
  • Hospitalization / statistics & numerical data
  • Humans
  • Length of Stay*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Patient Discharge / statistics & numerical data
  • Patient Readmission
  • Prognosis
  • Proportional Hazards Models
  • Pyridines / therapeutic use*
  • Survival Analysis
  • Tetrazoles / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Pyridines
  • Tetrazoles
  • tezosentan

Associated data

  • ClinicalTrials.gov/NCT00525707
  • ClinicalTrials.gov/NCT00524433